The National Institute for Health and Care Excellence (NICE) in the UK has approved Intercept Pharmaceuticals’ Ocaliva (obeticholic acid) for routine use by the National Health Service (NHS) in England, Wales and Northern Ireland.

It has been conditionally approved in the European Union to treat primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Ocaliva is expected to be available to patients with PBC within 90 days of NICE’s final appraisal publication.

Intercept Pharmaceuticals international president Lisa Bright said: “This very rapid decision by NICE, one of the fastest approvals to date for an orphan medication, is an important affirmation of the scientific innovation, clinical value and cost-effectiveness of Ocaliva by one of the most respected health technology assessment bodies.

“Ocaliva is expected to be available to patients with PBC within 90 days of NICE’s final appraisal publication.”

“We welcome NICE’s decision to provide broad access to Ocaliva and we owe a tremendous debt to people living with PBC and the clinical groups who helped us to achieve this milestone for the PBC community.”

Ocaliva is a new treatment option for patients with PBC.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In December last year, it received conditional marketing authorisation in Europe based on efficacy and safety data derived from three clinical trials.

The most commonly reported adverse reactions were pruritus (63%) and fatigue (22%).

PCB is a rare, autoimmune, cholestatic liver disease that puts patients at risk of life-threatening complications. It is primarily a disease in women, afflicting approximately one in 1,000 females older than 40.